Browsing Tag
Pancreatic Cancer
36 posts
Amplia Therapeutics (ASX: ATX) stock faces its next big test as narmafotinib moves deeper into cancer trials
Find out how Amplia Therapeutics’ FY2026 report frames ASX: ATX, narmafotinib trials, cash runway and investor sentiment today!
How the TIGeR-PaC sub-study could influence future thinking around chemotherapy tolerability and precision delivery
RenovoRx’s TIGeR-PaC sub-study highlights how targeted chemotherapy delivery could reshape pancreatic cancer treatment strategy. Read more.
Can Namodenoson overcome immunotherapy resistance in advanced pancreatic adenocarcinoma?
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
Could oral elraglusib emerge as a combination backbone for RAS-targeted cancer therapies?
Actuate Therapeutics, Inc. is advancing oral elraglusib to target resistance biology in cancer. Discover what this means for oncology markets.
Can an A3 adenosine receptor agonist change the treatment ceiling in advanced pancreatic cancer
Can Can-Fite BioPharma Ltd.’s namodenoson change pancreatic cancer outcomes? Explore what its Phase 2a data means for investors and oncology strategy.
Vector Science & Therapeutics (TSXV: PAIN) targets intratumoral pancreatic cancer drug delivery with new microneedle catheter patent
Pancreatic cancer needs better local therapy. Vector Science & Therapeutics is betting its patent strategy can open a new delivery path.
Why pancreatic cancer clinicians and investors are closely watching AIM ImmunoTech’s next move
AIM ImmunoTech’s next Ampligen move could reshape pancreatic cancer treatment and investor sentiment. Find out what executives and markets are watching now.
Is elraglusib emerging as a new frontline option in metastatic PDAC?
Read how Actuate Therapeutics’ elraglusib Phase 2 survival data could reshape metastatic PDAC treatment and investor expectations.
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.